LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism. Its route of administration has not been specified. The drug acts as a selective agonist of the serotonin 5-HT2A receptor. It is said to be an analogue of LPH-5 with similar characteristics but with faster metabolism and a shorter duration of action. LPH-5 is a highly selective serotonin 5-HT2A receptor agonist that is under development for major depressive disorder and has shown antidepressant-like effects in animals. LPH-48 is under development by Lophora. As of May 2024, it is in preclinical research for alcoholism. The chemical structure of LPH-48 does not yet seem to have been disclosed. However, Lophora has patented selective serotonin 5-HT2A receptor agonists for treatment of depression and the company is said to have patent protection for LPH-48. Additionally, the structure of its close analogue LPH-5 is known and this compound is a phenylpiperidine derivative.
See also Cyclized phenethylamine Substituted 3-phenylpiperidine List of investigational hallucinogens and entactogens BMB-202
References
External links LPH-48 - Lophora Pipeline - Lophora FAQ - Lophora